Literature DB >> 9537821

Pharmacological profile of antidepressants and related compounds at human monoamine transporters.

M Tatsumi1, K Groshan, R D Blakely, E Richelson.   

Abstract

Using radioligand binding assays, we determined the equilibrium dissociation constants (KD's) for 37 antidepressants, three of their metabolites (desmethylcitalopram, desmethylsertraline, and norfluoxetine), some mood stabilizers, and assorted other compounds (some antiepileptics, Ca2+ channel antagonists, benzodiazepines, psychostimulants, antihistamines, and monoamines) for the human serotonin, norepinephrine, and dopamine transporters. Among the compounds that we tested, mazindol was the most potent at the human norepinephrine and dopamine transporters with KD's of 0.45 +/- 0.03 nM and 8.1 +/- 0.4 nM, respectively. Sertraline (KD = 25 +/- 2 nM) and nomifensine (56 +/- 3 nM) were the two most potent antidepressants at the human dopamine transporter. We showed significant correlations for antidepressant affinities at binding to serotonin (R = 0.93), norepinephrine (R = 0.97), and dopamine (R = 0.87) transporters in comparison to their respective values for inhibiting uptake of monoamines into rat brain synaptosomes. These data are useful in predicting some possible adverse effects and drug-drug interactions of antidepressants and related compounds.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9537821     DOI: 10.1016/s0014-2999(97)01393-9

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  227 in total

1.  Antidepressants and upper gastrointestinal bleeding.

Authors:  A L Po
Journal:  BMJ       Date:  1999-10-23

2.  The antidepressant sertraline targets intracellular vesiculogenic membranes in yeast.

Authors:  Meredith M Rainey; Daniel Korostyshevsky; Sean Lee; Ethan O Perlstein
Journal:  Genetics       Date:  2010-05-10       Impact factor: 4.562

3.  Molecular mechanism of serotonin transporter inhibition elucidated by a new flexible docking protocol.

Authors:  Mari Gabrielsen; Rafał Kurczab; Aina W Ravna; Irina Kufareva; Ruben Abagyan; Zdzisław Chilmonczyk; Andrzej J Bojarski; Ingebrigt Sylte
Journal:  Eur J Med Chem       Date:  2011-10-20       Impact factor: 6.514

Review 4.  Pharmacology of serotonin: what a clinician should know.

Authors:  F De Ponti
Journal:  Gut       Date:  2004-10       Impact factor: 23.059

Review 5.  The solute carrier 6 family of transporters.

Authors:  Stefan Bröer; Ulrik Gether
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

Review 6.  Substrate and drug binding sites in LeuT.

Authors:  Ajeeta Nyola; Nathan K Karpowich; Juan Zhen; Jennifer Marden; Maarten E Reith; Da-Neng Wang
Journal:  Curr Opin Struct Biol       Date:  2010-06-16       Impact factor: 6.809

7.  Drug-drug interactions: is there an optimal way to study them?

Authors:  L D Lewis
Journal:  Br J Clin Pharmacol       Date:  2010-12       Impact factor: 4.335

8.  Evaluation of [(11)C]MRB for assessment of occupancy of norepinephrine transporters: Studies with atomoxetine in non-human primates.

Authors:  Jean-Dominique Gallezot; David Weinzimmer; Nabeel Nabulsi; Shu-Fei Lin; Krista Fowles; Christine Sandiego; Timothy J McCarthy; R Paul Maguire; Richard E Carson; Yu-Shin Ding
Journal:  Neuroimage       Date:  2010-09-30       Impact factor: 6.556

9.  Structure and localisation of drug binding sites on neurotransmitter transporters.

Authors:  Aina W Ravna; Ingebrigt Sylte; Svein G Dahl
Journal:  J Mol Model       Date:  2009-02-24       Impact factor: 1.810

10.  Pharmacological profile of novel psychoactive benzofurans.

Authors:  Anna Rickli; Simone Kopf; Marius C Hoener; Matthias E Liechti
Journal:  Br J Pharmacol       Date:  2015-04-24       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.